ABSTR 0949 – Proffered Oral Presentation: Phase II Study of Weekly Paclitaxel as Third-Line Chemotherapy for Advanced or Recurrent Gastric Cancer (OGSG0602)

摘要

Background:Median survival time was longer than 1 year in recent randomized phase III studies in advanced or recurrent gastric cancer (GC) conducted in Japan. Although progression-free survival after first-line chemotherapy has improved, many patients go on to receive second-line or later therapies with new agents such as paclitaxel or docetaxel, which may contribute to prolongation of overall survival. This study evaluated the efficacy and safety of weekly paclitaxel as third-line chemotherapy in patients with advanced or recurrent GC.